Relay Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Relay Therapeutics, Inc. (RLAY) reported Capital Expenditures Incurred but Not yet Paid of $159.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-02-23
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$906.00K, a 192.73% decline year-over-year.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $396.00K.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was -$883.00K, a 190.38% decline year-over-year.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $1.55M, a 1452.00% increase year-over-year.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $159.00K, a 84.26% decline from fiscal 2021.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $1.01M, a 94.61% increase from fiscal 2020.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $519.00K, a 30.34% decline from fiscal 2019.
- Relay Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2019 was $745.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$510.00K derived: sum of 2 quarters · filed 2023-02-23 | -$1.39M derived: sum of 3 quarters · filed 2023-02-23 | $159.00K 10-K · filed 2023-02-23 |
| 2022-09-30 | $396.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$487.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.06M 10-Q · filed 2022-11-03 | $2.04M derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-06-30 | -$883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $669.00K 10-Q · filed 2022-08-04 | $1.65M derived: sum of 3 quarters · filed 2023-02-23 | $602.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-03-31 | $1.55M 10-Q · filed 2022-05-05 | $2.53M derived: sum of 2 quarters · filed 2023-02-23 | $1.49M derived: sum of 3 quarters · filed 2023-02-23 | $2.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-12-31 | $977.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$67.00K derived: sum of 2 quarters · filed 2023-02-23 | $910.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.01M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$67.00K derived: sum of 2 quarters · filed 2022-11-03 | $33.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $977.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.08M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $519.00K 10-K · filed 2023-02-23 | |||
| 2020-06-30 | $279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $330.00K 10-Q · filed 2021-08-12 | $1.05M derived: sum of 3 quarters · filed 2022-02-24 | -$87.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $51.00K 10-Q · filed 2021-05-13 | $772.00K derived: sum of 2 quarters · filed 2022-02-24 | -$366.00K derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $721.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$417.00K derived: sum of 2 quarters · filed 2022-02-24 | $745.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $24.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $1.16M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |